Scholarlink

<p>Drug resistance remains a major challenge in the treatment of ovarian cancer and is a leading cause of recurrence and poor clinical outcomes. Increasing evidence has identified acetylation as a critical epigenetic and post-translational modification that contributes to therapeutic resistance through the regulation of chromatin accessibility, gene transcription, protein function, and cellular signaling. Recent studies suggest that acetylation functions as an integrative regulatory hub linking multiple resistance-associated processes, including DNA damage repair, cancer stemness, cellular plasticity, metabolic adaptation, and immune evasion. In this review, we summarize the molecular mechanisms by which histone and non-histone acetylation, together with acetylation-associated regulatory networks, drive ovarian cancer drug resistance. We further discuss current advances in acetylation-targeted therapeutic strategies, including HDAC inhibitors, BET inhibitors, emerging KAT inhibitors, and rational combination approaches designed to overcome resistance. Collectively, acetylation-centered regulatory networks represent promising therapeutic targets in ovarian cancer. A deeper understanding of these mechanisms may facilitate biomarker-guided patient stratification and support the development of more effective strategies for overcoming drug resistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Acetylation in ovarian cancer: mechanistic insights into drug resistance and emerging therapeutic opportunities

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月4日

查看全文
  • Shujie Chen,
  • Qinhong He,
  • Yunxiao He,
  • Jingji Jin,
  • Aiping Wen

摘要

Drug resistance remains a major challenge in the treatment of ovarian cancer and is a leading cause of recurrence and poor clinical outcomes. Increasing evidence has identified acetylation as a critical epigenetic and post-translational modification that contributes to therapeutic resistance through the regulation of chromatin accessibility, gene transcription, protein function, and cellular signaling. Recent studies suggest that acetylation functions as an integrative regulatory hub linking multiple resistance-associated processes, including DNA damage repair, cancer stemness, cellular plasticity, metabolic adaptation, and immune evasion. In this review, we summarize the molecular mechanisms by which histone and non-histone acetylation, together with acetylation-associated regulatory networks, drive ovarian cancer drug resistance. We further discuss current advances in acetylation-targeted therapeutic strategies, including HDAC inhibitors, BET inhibitors, emerging KAT inhibitors, and rational combination approaches designed to overcome resistance. Collectively, acetylation-centered regulatory networks represent promising therapeutic targets in ovarian cancer. A deeper understanding of these mechanisms may facilitate biomarker-guided patient stratification and support the development of more effective strategies for overcoming drug resistance.